Clinical efficacy and cardiac toxicity associated with first-line dabrafenib plus trametinib in advanced BRAF V600_K601delinsE-mutated lung adenocarcinoma: a case report and literature review

The BRAF V600_K601delinsE (c.1799_1801del) mutation is rare, with an estimated prevalence of 0.05% among all tumor types. Therapeutic options for advanced lung adenocarcinoma harboring this mutation are limited. We present a case of a patient with advanced lung adenocarcinoma carrying the BRAF V600_K601delinsE mutation who derived clinical benefit for one year from treatment with dabrafenib plus trametinib. The patient subsequently developed biventricular asynergy and a significant reduction in left ventricular ejection fraction (LVEF). This case of drug-induced cardiomyopathy is presented in the context of this known adverse reaction, which affects nearly 6% of patients receiving this combination regimen. This report contributes experience on the management of this rare genomic subtype and offers perspectives on addressing its associated adverse drug reactions.